Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis WorseningVlad Ratziu, Juan F. Gallegos‐Orozco, Velimir A. Luketic et al.|Gastroenterology|2016Cited by 1k
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trialJordi Bruix, Josep M. Llovet, Jean‐Luc Raoul et al.|Journal of Hepatology|2012Cited by 821
A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosisScott L. Friedman, Éric Lefebvre, Vlad Ratziu et al.|Hepatology|2017Cited by 657
Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular diseasePaola Dongiovanni, Luca Valenti, Silvia Fargion et al.|Hepatology|2014Cited by 529
Impact of COVID-19 on global HCV elimination effortsSarah Blach, Antonio Craxı̀, Loreta A. Kondili et al.|Journal of Hepatology|2020Cited by 279